PLoS Pathogens (May 2023)

Identification of CDRH3 loops in the B cell receptor repertoire that can be engaged by candidate immunogens.

  • Olivia Swanson,
  • Joshua S Martin Beem,
  • Brianna Rhodes,
  • Avivah Wang,
  • Maggie Barr,
  • Haiyan Chen,
  • Robert Parks,
  • Kevin O Saunders,
  • Barton F Haynes,
  • Kevin Wiehe,
  • Mihai L Azoitei

DOI
https://doi.org/10.1371/journal.ppat.1011401
Journal volume & issue
Vol. 19, no. 5
p. e1011401

Abstract

Read online

A major goal for the development of vaccines against rapidly mutating viruses, such as influenza or HIV, is to elicit antibodies with broad neutralization capacity. However, B cell precursors capable of maturing into broadly neutralizing antibodies (bnAbs) can be rare in the immune repertoire. Due to the stochastic nature of B cell receptor (BCR) rearrangement, a limited number of third heavy chain complementary determining region (CDRH3) sequences are identical between different individuals. Thus, in order to successfully engage broadly neutralizing antibody precursors that rely on their CDRH3 loop for antigen recognition, immunogens must be able to tolerate sequence diversity in the B cell receptor repertoire across an entire vaccinated population. Here, we present a combined experimental and computational approach to identify BCRs in the human repertoire with CDRH3 loops predicted to be engaged by a target immunogen. For a given antibody/antigen pair, deep mutational scanning was first used to measure the effect of CDRH3 loop substitution on binding. BCR sequences, isolated experimentally or generated in silico, were subsequently evaluated to identify CDRH3 loops expected to be bound by the candidate immunogen. We applied this method to characterize two HIV-1 germline-targeting immunogens and found differences in the frequencies with which they are expected to engage target B cells, thus illustrating how this approach can be used to evaluate candidate immunogens towards B cell precursors engagement and to inform immunogen optimization strategies for more effective vaccine design.